{"id":4403,"date":"2026-06-08T02:02:48","date_gmt":"2026-06-07T21:02:48","guid":{"rendered":"https:\/\/bondstonelaw.com\/?post_type=industries&p=4403"},"modified":"2026-08-28T21:54:43","modified_gmt":"2026-08-28T16:54:43","slug":"pharmaceuticals-and-healthcare-in-kazakhstan","status":"publish","type":"industries","link":"https:\/\/bondstonelaw.com\/ru\/industries\/pharmaceuticals-and-healthcare-in-kazakhstan\/","title":{"rendered":"Pharmaceuticals & Healthcare"},"content":{"rendered":"

INDUSTRY \u00a0\u00b7\u00a0 PHARMACEUTICALS & HEALTHCARE<\/strong><\/p>\n

Pharmaceuticals and Healthcare in Kazakhstan & Central Asia<\/h1>\n

The pharmaceuticals and healthcare sector is among the fastest-growing industries in Central Asia, driven by rising consumer spending, government modernisation programmes, and increasing foreign investment in hospital infrastructure, pharmaceutical manufacturing, and medical technology distribution. Kazakhstan has positioned healthcare as a national strategic priority under successive development programmes, investing in hospital network expansion, health insurance reform, and domestic pharmaceutical production. Uzbekistan and Kyrgyzstan present significant growth opportunities for international pharmaceutical companies, medical device distributors, and private healthcare investors as both markets open to foreign participation.<\/p>\n

Bond Stone advises pharmaceutical companies, medical device manufacturers, healthcare investors, distributors, and multinational corporations entering or expanding in the Central Asian healthcare market. Our work spans regulatory approval and market access, distribution agreement structuring, pharmaceutical manufacturing joint ventures, hospital development investment, and healthcare dispute resolution. We advise clients in Kazakhstan, Uzbekistan, and Kyrgyzstan and structure cross-border holdings through AIFC vehicles where appropriate.<\/p>\n

Pharmaceutical regulation and healthcare licensing in Central Asia involves multiple state agencies, mandatory local registration of medicinal products, state pricing controls, and public procurement regulations that significantly affect commercial viability. International companies entering this market without experienced in-country counsel frequently encounter preventable delays and compliance exposure.<\/p>\n

\n

Central Asia Pharmaceuticals & Healthcare \u2014 Key Segments<\/h2>\n

<\/p>\n

\n
\n
USD 2B+<\/div>\n
Kazakhstan pharmaceutical market size (2024 estimate)<\/div>\n<\/div>\n
\n
35M+<\/div>\n
Combined population of KZ, UZB & KG \u2014 the core Central Asian consumer market<\/div>\n<\/div>\n
\n
2025<\/div>\n
Kazakhstan mandatory health insurance (OSMS) fully operational<\/div>\n<\/div>\n
\n
50%<\/div>\n
Kazakhstan’s target for domestic pharmaceutical production by 2025<\/div>\n<\/div>\n<\/div>\n

<\/p>\n

\n

Pharmaceutical Registration & Market Access<\/h3>\n

Medicinal products must be registered with the relevant national authority before being placed on the market in each Central Asian jurisdiction. In Kazakhstan, registration is conducted through the National Centre for Expertise of Medicines and Medical Devices (NC EKSMED) under the Ministry of Healthcare. The Eurasian Economic Union (EAEU) Unified Pharmaceutical Market \u2014 of which Kazakhstan is a member \u2014 has progressively harmonised drug registration procedures, with mutual recognition agreements enabling EAEU-registered products to access multiple markets through a single dossier procedure. Uzbekistan and Kyrgyzstan operate independent national registration systems administered by their respective Ministry of Health agencies.<\/p>\n

Bond Stone assists pharmaceutical companies in navigating registration procedures, preparing localised regulatory documentation, engaging with state agencies on registration timelines, and structuring market access arrangements including exclusive distribution rights and local representative agreements mandated by applicable law.<\/p>\n<\/div>\n

<\/p>\n

\n

Distribution Agreements & Commercial Structures<\/h3>\n

International pharmaceutical companies typically access Central Asian markets through local distributor or commercial representative arrangements, as retail pharmaceutical distribution requires local licences and state registration of the distributing entity in each jurisdiction. Kazakhstan’s Law on Healthcare (Law No. 360-VI, 2020) and the Rules on Licensing of Pharmaceutical Activity set the framework for pharmaceutical wholesale and retail licences. Distribution agreements with Kazakhstani or Uzbek partners require careful structuring to address exclusivity, pricing controls under the List of Essential Medicines (LEMs), anti-bribery and anti-corruption compliance under local law and FCPA\/UK Bribery Act obligations, and termination and intellectual property protection provisions.<\/p>\n

Bond Stone drafts and reviews distribution, agency, and local representative agreements, advises on anti-corruption compliance frameworks for pharmaceutical distribution, and assists with licence transfer or assignment in connection with changes of distributor.<\/p>\n<\/div>\n

<\/p>\n

\n

Pharmaceutical Manufacturing & Joint Ventures<\/h3>\n

Kazakhstan’s government has prioritised domestic pharmaceutical manufacturing as a strategic policy objective, offering investors in GMP-certified pharmaceutical production facilities access to preferential state procurement pricing, tax incentives, and Special Economic Zone benefits. Joint ventures between international pharmaceutical manufacturers and Kazakhstani state-linked entities (including JSC SK-Pharmacy, a subsidiary of Samruk-Kazyna) are a common structuring approach. Technology transfer agreements, intellectual property licensing, and Good Manufacturing Practice (GMP) certification coordination are key legal components of such arrangements. In Uzbekistan, pharmaceutical manufacturing investment in designated free economic zones offers similar incentive packages.<\/p>\n

Bond Stone advises on JV structuring for pharmaceutical manufacturing investments, technology transfer and IP licensing agreements, GMP certification coordination, and state procurement framework compliance for locally manufactured products.<\/p>\n<\/div>\n

<\/p>\n

\n

Private Healthcare Investment & Hospital Development<\/h3>\n

Kazakhstan’s Compulsory Social Health Insurance (OSHI\/OSMS) system \u2014 operational since 2021 \u2014 has created a dual public-private healthcare market where private clinics and hospitals can enter into performance-based contracts with the Social Health Insurance Fund (FOMS), enabling internationally run facilities to compete for publicly funded patients. International hospital groups, private equity investors, and sovereign wealth funds have identified Kazakhstan and Uzbekistan as attractive markets for private hospital development, specialist clinic chains, and diagnostic imaging networks. Tashkent in particular has seen significant private hospital investment following Uzbekistan’s healthcare sector reforms beginning in 2019.<\/p>\n

Bond Stone advises private healthcare investors on facility licensing requirements, FOMS provider accreditation, investment structuring through AIFC or Kazakhstani SPVs, land and premises arrangements, and regulatory compliance for international medical staff employment.<\/p>\n<\/div>\n

<\/p>\n

\n

Medical Devices & Healthcare Technology<\/h3>\n

Medical devices are regulated separately from pharmaceuticals in Kazakhstan and Uzbekistan, with registration and import licensing requirements administered by the Ministry of Healthcare (Kazakhstan) and the Ministry of Health (Uzbekistan). The EAEU Technical Regulation TR EAEU 017\/2011 on Medical Devices applies to Kazakhstan and creates a common technical standard framework across EAEU member states. Medical technology companies \u2014 including diagnostic equipment manufacturers, surgical technology suppliers, and health IT providers \u2014 must navigate both product registration and customs import procedures. Telemedicine and digital health platforms are subject to emerging regulatory frameworks in Kazakhstan under the 2020 Healthcare Law.<\/p>\n

Bond Stone advises medical device companies on EAEU technical regulation compliance, Kazakhstani and Uzbek medical device registration, customs classification and import licensing, and commercial distribution agreement structuring.<\/p>\n<\/div>\n

\n

Bond Stone Pharmaceuticals & Healthcare Services<\/h2>\n

<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Service<\/th>\nJurisdictions<\/th>\n<\/tr>\n<\/thead>\n
Pharmaceutical product registration & market access<\/td>\nKazakhstan, Uzbekistan, Kyrgyzstan<\/td>\n<\/tr>\n
Distribution & commercial representative agreement drafting<\/td>\nAll jurisdictions<\/td>\n<\/tr>\n
Pharmaceutical manufacturing JV structuring<\/td>\nKazakhstan, Uzbekistan<\/td>\n<\/tr>\n
Anti-corruption compliance for pharmaceutical distribution<\/td>\nAll jurisdictions<\/td>\n<\/tr>\n
Private hospital & clinic investment structuring<\/td>\nKazakhstan, Uzbekistan<\/td>\n<\/tr>\n
Medical device registration & EAEU compliance<\/td>\nKazakhstan, EAEU<\/td>\n<\/tr>\n
SEZ & tax incentive structuring for manufacturing investors<\/td>\nKazakhstan, Uzbekistan<\/td>\n<\/tr>\n
Healthcare & pharmaceutical dispute resolution<\/td>\nAIFC Court, SIAC, domestic courts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Key Regulatory Framework<\/h2>\n\n\n\n\n\n\n\n
Jurisdiction<\/th>\nPrimary Law<\/th>\nKey Compliance Requirement<\/th>\n<\/tr>\n<\/thead>\n
Kazakhstan<\/td>\nLaw on Healthcare (Law No. 360-VI, 2020); Rules on Pharmaceutical Licensing<\/td>\nPharmaceutical activity licence; product registration with NC EKSMED; OSHI\/OSMS compliance<\/td>\n<\/tr>\n
Uzbekistan<\/td>\nLaw on Healthcare (1996, as amended); Ministry of Health Drug Registration Rules<\/td>\nMinistry of Health product registration; local authorised representative requirement<\/td>\n<\/tr>\n
EAEU<\/td>\nEAEU Treaty (2014); EAEU Rules on Medicinal Products Circulation; TR EAEU 017\/2011<\/td>\nUnified pharmaceutical market harmonisation; GMP certification for manufacturers<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n
\n

Representative Experience<\/h2>\n

Bond Stone’s pharmaceuticals and healthcare experience includes the following representative matters. Client confidentiality is maintained; sector, transaction type, and jurisdiction are disclosed where permitted.<\/p>\n

\n

International Drug Manufacturer \u2014 Kazakhstan Registration Strategy<\/strong>
\nAdvised a European pharmaceutical company on the registration of its product portfolio in Kazakhstan, covering MHSD registration dossier requirements, local authorised representative appointment, GMP certification alignment with EAEU requirements, and state procurement eligibility documentation for SSMC-listed medicines.<\/p>\n<\/div>\n

\n

Pharmaceutical Distribution Network \u2014 Central Asia Market Entry<\/strong>
\nAdvised an international pharmaceutical group on establishing a multi-country distribution network across Kazakhstan, Uzbekistan, and Kyrgyzstan, including distributor agreement structuring, regulatory compliance obligations by jurisdiction, anti-corruption clause requirements for government-linked distributor counterparties, and transfer pricing documentation strategy.<\/p>\n<\/div>\n

\n

Private Hospital Investment \u2014 Almaty, AIFC Holding Structure<\/strong>
\nAdvised a private equity-backed healthcare investor on the acquisition and development of a private hospital project in Almaty, including SPV structuring, investment contract negotiations with the Ministry of Healthcare, FOMS\/OSHI accreditation pathway advisory, and establishment of an AIFC-domiciled holding vehicle with AIFC Court dispute resolution provisions.<\/p>\n<\/div>\n

\n

Medical Device Licensing \u2014 Uzbekistan Market Entry<\/strong>
\nAdvised a South Korean medical device manufacturer on market entry into Uzbekistan, covering state registration requirements for medical devices with the Agency for Sanitary and Epidemiological Well-being, local authorised representative obligations, customs tariff classification, and distributor agreement structuring under Uzbek law.<\/p>\n<\/div>\n

\n

Pharma Manufacturing JV \u2014 Kazakhstan Localisation, EAEU Framework<\/strong>
\nAdvised a multinational pharmaceutical company on establishing a local manufacturing joint venture in Kazakhstan to satisfy import substitution and localisation requirements, covering JV documentation, EAEU unified pharmaceutical market manufacturing licence, technology transfer agreement structuring, and investment incentive eligibility under the Entrepreneurial Code of Kazakhstan.<\/p>\n<\/div>\n

\n

<\/p>\n

Pharmaceuticals & Healthcare Law \u2014 Frequently Asked Questions<\/h2>\n

Answers to the most common legal questions from pharmaceutical companies, healthcare investors, and medical device manufacturers entering Central Asian markets.<\/p>\n

\n

How do foreign pharmaceutical companies register drugs in Kazakhstan?<\/h3>\n

Pharmaceutical products must be registered with the National Centre for Expertise of Medicines and Medical Devices (NC EKSMED) under Kazakhstan’s Ministry of Healthcare before market entry. Registration requires a complete dossier including clinical data, manufacturing quality documentation, and GMP certification. As a member of the EAEU Unified Pharmaceutical Market, Kazakhstan allows EAEU mutual recognition for products registered under the harmonised procedure. Bond Stone assists in preparing registration dossiers, engaging with state agencies, and structuring the local authorised representative arrangements required under Kazakhstani pharmaceutical law.<\/p>\n<\/div>\n

\n

What is the EAEU Unified Pharmaceutical Market and how does it affect drug registration in Kazakhstan?<\/h3>\n

The EAEU Unified Pharmaceutical Market harmonises drug registration across Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan. Under the EAEU Rules on Medicinal Products Circulation, a product registered through the EAEU mutual recognition procedure can access multiple member state markets without a separate national dossier in each. GMP certification aligned with EAEU standards is a mandatory prerequisite for manufacturers. Bond Stone advises on EAEU registration strategy, mutual recognition applications, and GMP coordination for foreign pharmaceutical companies targeting multiple Central Asian markets simultaneously.<\/p>\n<\/div>\n

\n

What distribution structure is required for a foreign pharma company to sell in Kazakhstan?<\/h3>\n

Foreign pharmaceutical companies must appoint a locally licensed Kazakhstani entity for wholesale and retail distribution. This typically involves a local authorised representative (a licenced Kazakhstani entity) for registration and regulatory purposes, and a commercial distributor for sales. Distribution agreements must address exclusivity, List of Essential Medicines (LEM) pricing controls, anti-corruption compliance (FCPA\/UK Bribery Act) for dealings with state-linked counterparties, and IP protection provisions. Bond Stone drafts and reviews these agreements and advises on anti-corruption compliance frameworks specific to the pharmaceutical sector.<\/p>\n<\/div>\n

\n

What GMP certification is required for pharmaceutical manufacturers supplying Kazakhstan?<\/h3>\n

Manufacturers must hold GMP certification meeting EAEU GMP standards. EAEU GMP certificates issued by any EAEU member state authority are accepted across the union. For manufacturers outside the EAEU, Kazakhstan’s Ministry of Healthcare may require an EAEU GMP inspection of the manufacturing site, or may recognise equivalent certificates (EU GMP, US FDA) on a case-by-case basis. GMP certification is a mandatory prerequisite for product registration. Bond Stone coordinates GMP certification processes for international manufacturers and advises on EAEU manufacturing licence requirements for local production joint ventures.<\/p>\n<\/div>\n

\n

How can foreign investors structure a private hospital investment in Kazakhstan?<\/h3>\n

Foreign investors may develop and operate private hospitals in Kazakhstan through a locally incorporated TOO (LLC) or AO (JSC) holding a healthcare activity licence from the Ministry of Healthcare. Access to publicly funded patients requires FOMS accreditation under the Compulsory Social Health Insurance (OSHI\/OSMS) system. Cross-border holding structures typically use an AIFC SPV or Kazakhstani JSC as the investment vehicle, with AIFC Court dispute resolution. Bond Stone advises private equity and strategic healthcare investors on facility licensing, FOMS accreditation, investment structuring, and regulatory compliance for international medical staff employment.<\/p>\n<\/div>\n

<\/p>\n

\n

Why Bond Stone for Pharmaceuticals & Healthcare<\/h2>\n

\u2014<\/strong>In-country offices in Almaty, Astana, Tashkent, and Bishkek \u2014 direct access to healthcare regulators, licensing authorities, and Ministry of Health contacts in all core markets<\/p>\n

\u2014<\/strong>Experience structuring pharmaceutical distribution networks and advising international companies on anti-corruption compliance requirements applicable to healthcare sector dealings with government-linked counterparties<\/p>\n

\u2014<\/strong>Understanding of the EAEU Unified Pharmaceutical Market and the mutual recognition framework for drug registration across Kazakhstan and other EAEU member states<\/p>\n

\u2014<\/strong>Track record advising private healthcare investors on hospital project structuring in Kazakhstan and Uzbekistan, including FOMS\/OSHI accreditation and local regulatory compliance<\/p>\n

\u2014<\/strong>AIFC-capable for cross-border holding structures \u2014 enabling international healthcare groups to use AIFC SPVs with AIFC Court dispute resolution for regional investment platforms<\/p>\n

\u2014<\/strong>Trilingual capability (English, Russian, Kazakh) for regulatory filings, Ministry of Health submissions, and commercial negotiations<\/p>\n

\u2014<\/strong>Ranked by Legal 500 EMEA and IFLR1000 for corporate and regulatory practice across the region<\/p>\n<\/div>\n

\n

<\/p>\n

Related Practice Areas<\/h2>\n

Pharmaceutical and healthcare mandates in Central Asia regularly engage regulatory, corporate, and data protection disciplines. Bond Stone provides integrated coverage across all relevant practice areas.<\/p>\n\n\n\n
\n
Regulatory & Licensing<\/div>\n
Drug registration, pharmaceutical licence applications, and regulatory submissions to Kazakhstan’s MHSD and Uzbekistan’s Ministry of Health.<\/div>\n

VIEW PRACTICE \u2192<\/a><\/td>\n

\n
Corporate & Commercial Law<\/div>\n
Distribution agreements, manufacturing JV structuring, supply contracts, and commercial documentation for pharmaceutical companies entering Central Asian markets.<\/div>\n

VIEW PRACTICE \u2192<\/a><\/td>\n

\n
Investment in Kazakhstan<\/div>\n
Investment contract structures for private healthcare facilities, local content compliance, SEZ incentives, and repatriation of profits from healthcare investments.<\/div>\n

VIEW PRACTICE \u2192<\/a><\/td>\n

\n
Data Protection<\/div>\n
Personal health data compliance under Kazakhstan’s Law on Personal Data, cross-border data transfer requirements, and clinical trial data governance frameworks.<\/div>\n

VIEW PRACTICE \u2192<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n

<\/p>\n

Pharmaceuticals & Healthcare \u2014 Key Legal Topics<\/h2>\n

In-depth guidance on the regulatory and commercial issues most frequently encountered by pharmaceutical companies and healthcare investors operating in Kazakhstan, Uzbekistan, and Kyrgyzstan.<\/p>\n\n\n\n
\n
Regulatory<\/div>\n
Drug Registration in Kazakhstan & the EAEU<\/div>\n
MHSD drug registration procedures, EAEU unified pharmaceutical market mutual recognition framework, GMP certification requirements, and accelerated registration pathways for innovative medicines.<\/div>\n

READ MORE \u2192<\/a><\/td>\n

\n
Distribution<\/div>\n
Pharmaceutical Distribution & Localisation<\/div>\n
Distributor agreement structuring, state procurement participation (SSMC framework), local manufacturing partnership requirements, and localisation obligations for foreign pharmaceutical companies in Kazakhstan.<\/div>\n

READ MORE \u2192<\/a><\/td>\n

\n
Investment<\/div>\n
Private Healthcare Investment Structures<\/div>\n
Private hospital and clinic project structuring in Kazakhstan, FOMS\/OSHI accreditation advisory, AIFC holding vehicle options for regional healthcare investment platforms, and public-private healthcare concessions.<\/div>\n

READ MORE \u2192<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\n

<\/p>\n

\n

Entering the Central Asian Pharmaceuticals or Healthcare Market?<\/h3>\n

Bond Stone provides legal advisory on pharmaceutical registration, distribution structuring, manufacturing joint ventures, private healthcare investment, and medical device licensing across Kazakhstan, Uzbekistan, and Kyrgyzstan.<\/p>\n\n\n\n
Contact Bond Stone \u2192<\/span><\/a><\/td>\nRegulatory Licensing \u2192<\/span><\/a><\/td>\nInvestment in Kazakhstan \u2192<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

<\/p>\n

\n\n\n\n
\n
\u2190 Previous Industry<\/div>\n
\n
Next Industry \u2192<\/div>\n
Maritime & Shipping<\/a><\/div>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Market entry, drug registration, and distribution agreement structuring for international pharmaceutical companies entering Kazakhstan.<\/p>\n","protected":false},"featured_media":0,"menu_order":4,"template":"","class_list":["post-4403","industries","type-industries","status-publish","hentry"],"translation":{"provider":"WPGlobus","version":"3.0.5","language":"ru","enabled_languages":["en","ru"],"languages":{"en":{"title":true,"content":true,"excerpt":true},"ru":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/bondstonelaw.com\/ru\/wp-json\/wp\/v2\/industries\/4403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bondstonelaw.com\/ru\/wp-json\/wp\/v2\/industries"}],"about":[{"href":"https:\/\/bondstonelaw.com\/ru\/wp-json\/wp\/v2\/types\/industries"}],"wp:attachment":[{"href":"https:\/\/bondstonelaw.com\/ru\/wp-json\/wp\/v2\/media?parent=4403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}